Interferon-induced thyroid dysfunction in chronic hepatitis C

Journal of Gastroenterology and Hepatology (Australia)

Volumn 24, Issue 6, 2009, Pages 1017-1023

  Jamil, Khaleel M ^a,b   Leedman, Peter J ^b,c,d   Kontorinis, Nickolas ^b   Tarquinio, Lorenzo ^b   Nazareth, Saroja ^b   McInerney, Marion ^b   Connelly, Crystal ^b   Flexman, James ^b   Burke, Valerie ^d   Metcalf, Cecily ^b   Cheng, Wendy ^b  

^a UNIVERSITY HOSPITAL LEWISHAM   (United Kingdom)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c ROYAL PERTH HOSPITAL   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Autoimmune thyroid disease; Hepatitis C; Interferon; TPO antibodies

Indexed keywords

ALPHA INTERFERON; CARBIMAZOLE; PEGINTERFERON ALPHA; PROPRANOLOL; RADIOACTIVE IODINE; RIBAVIRIN; THYROID PEROXIDASE ANTIBODY; THYROXINE;

ADULT; ARTICLE; ASIAN; CHI SQUARE TEST; CHRONIC DISEASE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CYTOLOGY; ETHNICITY; FEMALE; FISHER EXACT TEST; FOLLOW UP; GENDER; HEPATITIS C; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INCIDENCE; MALE; MONOTHERAPY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STUDENT T TEST; THYROID DISEASE; THYROID FUNCTION TEST; THYROIDITIS;

ADULT; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RIBAVIRIN; RISK FACTORS; SEX FACTORS; THYROID DISEASES; THYROID FUNCTION TESTS; WESTERN AUSTRALIA;

EID: 66549115114     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2008.05690.x     Document Type: Article

References (26)

1. Law MG, Dore GJ, Bath N et al. Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. Int. J. Epidemiol. 2003 32 : 717 24.
2. Brok J, Gluud LL, Gluud C. Effects of adding ribavirin to interferon to treat chronic hepatitis C infection: a systematic review and meta-analysis of randomized trials. Arch. Intern. Med. 2005 165 : 2206 12.
3. McHutchison JG, Manns M, Patel K et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002 123 : 1061 9.
4. Morisco F, Mazziotti G, Rotondi M et al. Interferon-related thyroid autoimmunity and long-term clinical outcome of chronic hepatitis C. Dig. Liver Dis. 2001 33 : 247 53.
5. Fernandez-Soto L, Gonzalez A, Escobar-Jimenez F et al. Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy. Arch. Intern. Med. 1998 158 : 1445 8.
6. Tran HA, Attia JR, Jones TL, Batey RG. Pegylated interferon- α2β in combination with ribavirin does not aggravate thyroid dysfunction in comparison to regular interferon-α2β in a hepatitis C population: meta-analysis. J. Gastroenterol. Hepatol. 2007 22 : 472 6.
7. Watanabe U, Hashimoto E, Hisamitsu T, Obata H, Hayashi N. The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C. Am. J. Gastroenterol. 1994 89 : 399 403. (Pubitemid 24074402)
8. Deutsch M, Dourakis S, Manesis EK et al. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology 1997 26 : 206 10.
9. Dalgard O, Bjoro K, Hellum K et al. Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy. J. Intern. Med. 2002 251 : 400 6.
10. Marazuela M, Garcia-Buey L, Gonzalez-Fernandez B et al. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clin. Endocrinol. (Oxf.) 1996 44 : 635 42.
11. Carella C, Mazziotti G, Amato G, Braverman LE, Roti E. Clinical review 169: interferon-alpha-related thyroid disease: pathophysiological, epidemiological, and clinical aspects. J. Clin. Endocrinol. Metab. 2004 89 : 3656 61.
12. Okanoue T, Sakamoto S, Itoh Y et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J. Hepatol. 1996 25 : 283 91.
13. Tran HA, Jones TL, Batey RG. The spectrum of thyroid dysfunction in an Australian hepatitis C population treated with combination Interferon-alpha2beta and Ribavirin. BMC Endocr. Disord. 2005 5 : 8.
14. Roti E, Minelli R, Giuberti T et al. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am. J. Med. 1996 101 : 482 7.
15. Sato K, Satoh T, Shizume K et al. Inhibition of 125I organification and thyroid hormone release by interleukin-1, tumor necrosis factor-alpha, and interferon-gamma in human thyrocytes in suspension culture. J. Clin. Endocrinol. Metab. 1990 70 : 1735 43.
16. Hultgren C, Milich DR, Weiland O, Sallberg M. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J. Gen. Virol. 1998 79 : 2381 91.
17. Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 1994 370 : 650 2.
18. Tam RC, Pai B, Bard J et al. Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J. Hepatol. 1999 30 : 376 82.
19. Carella C, Mazziotti G, Morisco F et al. The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism. Eur. J. Endocrinol. 2002 146 : 743 9.
20. Jayaram HN, Cooney DA, Grusch M, Krupitza G. Consequences of IMP dehydrogenase inhibition, and its relationship to cancer and apoptosis. Curr. Med. Chem. 1999 6 : 561 74.
21. Yalowitz JA, Jayaram HN. Molecular targets of guanine nucleotides in differentiation, proliferation and apoptosis. Anticancer Res. 2000 20 : 2329 38.
22. Koh LK, Greenspan FS, Yeo PP. Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature. Thyroid 1997 7 : 891 6.
23. Floreani A, Chiaramonte M, Greggio NA et al. Organ-specific autoimmunity and genetic predisposition in interferon-treated HCV-related chronic hepatitis patients. Ital. J. Gastroenterol. Hepatol. 1998 30 : 71 6.
24. Tran A, Quaranta JF, Benzaken S et al. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology 1993 18 : 253 7.
25. Parana R, Cruz M, Lyra L, Cruz T. Subacute thyroiditis during treatment with combination therapy (interferon plus ribavirin) for hepatitis C virus. J. Viral. Hepat. 2000 7 : 393 5.
26. Parana R, Cruz M, Santos-Jesus R, Ferreira K, Codes L, Cruz T. Thyroid disease in HCV carriers undergoing antiviral therapy with interferon plus ribavirin. Braz. J. Infect. Dis. 2000 4 : 284 90.